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Lateral canthal lines or crow’s feet lines (CFL) may be treated with onabotulinumtoxinA. We identified several key concepts important to understanding the
use of onabotulinumtoxinA for treatment of moderate-to-severe CFL. To contextualize and integrate data on the recommended dose and injection patterns
of onabotulinumtoxinA for treatment of CFL, we summarized data from pivotal clinical studies in the development of onabotulinumtoxinA for treatment of
CFL. Data from key studies of onabotulinumtoxinA for CFL are presented. The efficacy and safety of onabotulinumtoxinA treatment of moderate-to-severe
CFL were evaluated in 2 randomized, controlled phase 3 studies comprising 1362 patients. The 24U total dose of onabotulinumtoxinA used in these
studies was based on a phase 2 dose-ranging trial. Two injection patterns were available to investigators; each involved 3 injection sites per side in the
lateral orbicularis oculi muscle. A cross-sectional analysis of photographs from the phase 3 trials provided detailed information on the frequency of 4 distinct
CFL patterns. In the primary efficacy analysis for each phase 3 trial, CFL responder rates were significantly greater with onabotulinumtoxinA vs placebo at
day 30 (P < .001). Eyelid edema (1%) was the only adverse event reported in ≥1% of patients receiving onabotulinumtoxinA, occurring more frequently
with onabotulinumtoxinA than with placebo. The studies showed that onabotulinumtoxinA is effective and generally well-tolerated for CFL treatment.
Additionally, 2 different injection patterns allow physicians to tailor treatment based on a patient’s CFL pattern.
Accepted for publication January 18, 2016; online publish-ahead-of-print March 15, 2016.
The use of onabotulinumtoxinA (Botox Cosmetic; Allergan,
Inc., Irvine, CA) for aesthetic treatment of facial lines has ex-
panded since its initial approval for temporary improvement in
the appearance of moderate-to-severe glabellar lines (GL).1
Lateral canthal lines, also known as crow’s feet lines (CFL),
are wrinkles that form around the eyes and are commonly
treated with onabotulinumtoxinA. Dynamic CFL form as a
result of repeated contraction of facial muscles involved in
smiling, notably the orbicularis oculi muscles.2,3 Static lines
may subsequently appear at rest, resulting from structural skin
remodeling during aging, repeated facial muscle contraction,
and damage from excessive sun exposure.4 Several different
patterns of CFL have been described based on alignment of
wrinkles in the lateral canthal area.5,6 In one trial of aesthetical-
ly oriented women between 30 and 65 years of age, 82%
chose CFL as the facial feature most likely to be treated first.7
Additionally, the same cohort of women identified CFL as 1 of
the facial features that bothered them the most.7
The efficacy and safety of onabotulinumtoxinA in CFL
were demonstrated in 2 phase 3, randomized controlled trials
comprising 1362 patients with moderate or severe CFL.8,9
Based on these trials, the Food and Drug Administration
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(FDA) approved onabotulinumtoxinA in September 2013 for
temporary improvement in the appearance of moderate to
severe CFL associated with orbicularis oculi activity in
adults.8,9 The purpose of this article is to contextualize and
integrate the data supporting onabotulinumtoxinA treatment
of CFL, including the rationale for selecting the 24U total
dose and the basis for the 2 different recommended injection
patterns.
METHODS
Through clinical experience, the authors identified several
key concepts that are important to understanding the use of
onabotulinumtoxinA for treatment of moderate-to-severe
CFL. Support for these key concepts was derived from the
dose-ranging data that form the basis for the recommended
total dose of 24U of onabotulinumtoxinA, the cross-
sectional analysis of untreated patients that illustrates the
basis for offering 2 recommended injection patterns of
onabotulinumtoxinA, and the clinical trials that studied the
efficacy and safety of onabotulinumtoxinA at the recom-
mended treatment dose. It should be noted that dose
recommendations are not interchangeable among botuli-
num toxin products, and dosing cannot be converted using
any dose ratio. To analyze these concepts and to place the
dose and injection pattern into perspective, we summa-
rized data from relevant dose-ranging studies; analyses
of baseline clinical characteristics; and randomized,
placebo-controlled safety and registration studies in the
development of onabotulinumtoxinA for treatment of
moderate-to-severe CFL.
RESULTS
Treatment of Crow’s Feet Lines: Dose
Selection Based on Phase 2 Clinical Trials
Although earlier studies of onabotulinumtoxinA treatment of
CFL suggested a potential dose range that may be effective for
treatment,10,11 a phase 2, dose-ranging trial was undertaken
to further study the dose-response relationship. Patients
(N=162) with bilaterally symmetrical moderate or severe
CFL were randomly assigned to receive treatment with 1 of
several doses of onabotulinumtoxinA or placebo.12 Study
treatment was administered via intramuscular injection at 3
sites per side (total of 6 injections) in the lateral aspect of the
orbicularis oculi muscle. Each injection was 0.1 mL in
volume and contained onabotulinumtoxinA or placebo.
Overall, the mean age was 47 years, 88.9% were women, and
98.8% were white. At baseline, 60.5% of patients had severe
CFL, and 39.5% had moderate CFL. Of note, of patients ran-
domized to receive a 24U total dose (n=31), 74.2% had
severe CFL and 25.8% had moderate CFL at baseline; of pa-
tients randomized to receive a 12U total dose (n=33),
60.6% had severe CFL and 39.4% had moderate CFL at base-
line. The varied proportions of patients with baseline severity
of severe vs moderate CFL may have affected the relative re-
sponder rates for the 24U and 12U total doses.
The primary efficacy analysis was based on the investi-
gator’s assessment of CFL severity at maximum smile using
the Facial Wrinkle Scale (FWS) with photonumeric guide.12
The FWS is a validated 4-grade assessment tool (0= none,
1=mild, 2=moderate, 3= severe). At posttreatment day
30, the responder rate, defined as patients with an investi-
gator rating of mild or none at postbaseline time points on
the FWS at maximum smile, was significantly greater
(P< .05) in onabotulinumtoxinA 12U and 24U groups
compared with that in the placebo group (Figure 1). The re-
sponder rate was also greater for the 24U dose compared
with lower doses. No dose-related safety signals were ob-
served. Based on responder rates in this study, the 24U
dose was selected as the treatment dose in the subsequent
phase 3 development program.
Treatment of Crow’s Feet Lines: Two
Injection Patterns Based on 4 Crow’s Feet
Lines Patterns
An in-person evaluation of 100 patients identified 4 distinct
CFL patterns: full fan, lower fan, central fan, and upper fan
(Figure 2).5 The full-fan, lower-fan, and central-fan pat-
terns were predominant (90%), and the upper-fan pattern
was the least common (10%). Based on this observation,
2 injection patterns were available to investigators in the
2 phase 3 CFL trials (Figure 3).
The descriptive terminology for each of these 4 CFL pat-
terns was recently modified to emphasize the orientation of
lines in the lateral canthal area and adjacent facial regions.6
Figure 1. Responder rates (investigator rating of none or mild)
over time in patients with at least moderate crow’s feet lines.
P< .05 for onabotulinumtoxinA 24U vs placebo at all time
points through 120 days; P< .05 for onabotulinumtoxinA 12U
vs placebo at days 7, 30, and 120.
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Their distribution was then characterized in a cross-sectional
analysis of patients with moderate-to-severe CFL who partici-
pated in 3 separate onabotulinumtoxinA clinical trials, includ-
ing the 2 CFL pivotal trials.6 Baseline photographs of each
patient’s CFL areas were taken using standardized equipment
while the patient was at rest and while the patient was maxi-
mally smiling. Two investigators independently reviewed left-
sided oblique photographs and classified each patient’s CFL
pattern according to the scheme shown in Figure 2. Consensus
was reached between investigators whenever initial case
assessments differed.
The cross-sectional analysis included 1392 untreated
patients (2699 photographs at baseline).6 In the study
cohort, mean age was 48.8 years, 85.9% were women, and
85.5% were white. At maximum smile, lower fan (34.7%)
and central fan (32.8%) were the most common CFL pat-
terns, followed by full fan (28.4%), then upper fan (4.2%).6
These results were consistent with findings from the prior
analysis of 100 patients for which the lower-fan, central-fan,
and full-fan patterns were commonly seen, whereas the
upper-fan pattern was seen relatively infrequently. At rest,
full fan (33.9%) and lower fan (32.0%) were the most
common patterns, followed by central fan (27.7%), then
upper fan (6.4%). In patients with both dynamic and static
lines, 52.8% had the same CFL patterns at maximum smile
and at rest.
The distribution of CFL patterns was found to vary ac-
cording to baseline CFL severity and the patient’s age and
gender.6 The central-fan pattern predominated at maximum
smile in patients with moderate CFL, whereas the lower-fan
and full-fan patterns were most common in patients with
severe CFL. The central-fan pattern also predominated at
maximum smile in younger patients (aged ≤40 years),
whereas the full-fan pattern was most frequently seen in
Figure 2. Classification of crow’s feet lines patterns in untreated patients. In a full-fan pattern (A), lines project from the lateral
canthal area and extend into both the superior malar area and the tail of the brow. In a lower-fan pattern (B), lines are predomi-
nantly confined to the lateral canthal area and the superior malar area. In a central-fan pattern (C), lines are predominantly con-
fined to the lateral canthal area and do not extend into the superior malar area or lateral third of the brow. An upper-fan pattern
(D) has lines predominantly confined to the lateral canthal area and extend toward or into the lateral third of the brow.
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older patients. These data suggest that the CFL pattern at
maximum smile may progress from central or lower fan to
full fan in older patients and with greater CFL severity.6
However, it should be noted that the cross-sectional nature
of this analysis did not allow for definitive conclusions re-
garding progression over time from 1 fan pattern to another.
In terms of gender, the lower-fan pattern was predomi-
nant in men (53.6% at maximum smile; 52.4% at rest),
whereas the central-fan, lower-fan, and full-fan patterns
were each seen in about 30% of women at maximum smile
and at rest. The upper-fan pattern was seen rarely in men
(1.5% at maximum smile) and infrequently in women
(4.6%). The differing frequency in CFL patterns by gender
may reflect differences in how men and women smile, with
men having greater recruitment of cheek elevators.
Efficacy of OnabotulinumtoxinA in Phase 3
Clinical Trials
The phase 3 program evaluated the efficacy and safety of
onabotulinumtoxinA in the treatment of moderate to severe
CFL in 2 pivotal, double-blind, placebo-controlled, randomized,
multicenter trials.8,9 Together, these pivotal phase 3 studies
randomized 833 patients to receive onabotulinumtoxinA
and 529 patients to receive placebo. Study 18 evaluated
onabotulinumtoxinA in the treatment of CFL alone, whereas
study 29 also assessed simultaneous treatment of CFL and GL.
Both studies enrolled adults with bilaterally symmetrical
moderate-to-severe CFL at maximum smile, whereas study 2
also required patients to have moderate-to-severe GL at
maximum frown, which resulted in an older cohort with more
severe CFL at baseline. In study 1, patients were randomly as-
signed in a 1:1 ratio to receive a single blinded treatment of
onabotulinumtoxinA 24U or placebo.8 In study 2, patients were
randomly assigned 1:1:1 to receive onabotulinumtoxinA 24U
for CFL and placebo for GL, onabotulinumtoxinA 24U for CFL
and an additional 20U for GL, or placebo for both CFL and GL.9
The treatment for CFL was the same in both studies and
was delivered via injections into 3 sites of each orbicularis
oculi muscle with the choice of injection pattern based on
each patient’s CFL characteristics and the investigator’s dis-
cretion. Patients received a single treatment on day 1 in
study 1 and were then followed for 5 months.8 In compari-
son, patients received their assigned treatments on days 1
and 120 in study 2 and were followed for a total of
7 months.9 The treatment arms in each study were well
balanced with respect to demographic and baseline charac-
teristics. However, the cohort in study 2 was somewhat
Figure 3. Injection pattern and allowed modification for the treatment of crow’s feet lines (CFL). (A) CFL injection pattern. The
first injection was in the orbicularis oculi at the level of the lateral canthus, at least 1.5-2.0 cm temporal to the lateral canthus and
just temporal to the lateral orbital rim (marked as AX). The second injection was 1.0-1.5 cm above this first injection site and at an
approximately 30° angle medially (marked as BX). The third injection was 1.0-1.5 cm below the first injection site at an approxi-
mately 30° angle medially (marked as CX). (B) Modified CFL injection pattern. When CFL are below the lateral canthus, 3 injec-
tions may be given in a line angling from superoposterior to anteroinferior. The first injection is made in the same manner as
described above for site AX. The anteroinferior injection point should be lateral to a line drawn vertically from the lateral canthus
and superior to the maxillary prominence. A third injection point should be positioned at the midpoint along a line connecting the
superoposterior and anteroinferior injection points.
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older than the cohort in study 1 (mean ages: 49.5 and 46.4
years, respectively) and contained a greater proportion of
patients with baseline CFL at maximum smile rated as
severe (63.2% and 50.2%, respectively).
The primary efficacy measure in these phase 3 trials was
CFL severity at maximum smile as assessed using the 4-grade
FWSwith photonumeric guide; day 30 after treatment was des-
ignated as the primary time point. Both investigators and pa-
tients independently performed the FWS assessment. The
definition of a responder used for the pivotal trials differed
from that described above in the dose-ranging study. As re-
quested by the FDA, a responder was defined by a composite
of at least a 2-grade improvement from baseline in CFL severity
at maximum smile as assessed by both investigator and patient
on a per-patient basis.8,9 In both studies, the responder rates for
CFL were significantly greater with onabotulinumtoxinA com-
pared with placebo at day 30 (Table 1). As a secondary end-
point, responders were also defined by a grade of none or mild
on the FWS as assessed at maximum smile by the investigators.
The proportion of responders peaked within 30 days following
onabotulinumtoxinA treatment then declined slowly over time
(P<.001) in study 1 (Figure 4).
Safety of OnabotulinumtoxinA in Phase 3
Clinical Trials
General Safety
Adverse events occur within the first week following injection
of onabotulinumtoxinA and, while usually transient, may
have a duration of several months or longer.13 Adverse events
that may be associated with injection of onabotulinumtoxinA
include localized pain, infection, inflammation, tenderness,
swelling, erythema, and bleeding/bruising. Needle-related
pain and/or anxiety may result in vasovagal responses that
may include, for example, syncope or hypotension and may
require appropriate medical therapy. Local weakness of the in-
jected muscle represents the expected pharmacologic action of
botulinum toxin. However, weakness of nearby muscles may
also occur due to the spread of onabotulinumtoxinA.
Safety in Crow’s Feet Lines
Eyelid edema was reported by 5 of 526 patients (1%) who
were treated with onabotulinumtoxinA for CFL in the
phase 3 trials.8,9 In comparison, none of the 530 patients
who received placebo experienced eyelid edema. No other
adverse event was reported within 90 days following
treatment with onabotulinumtoxinA at an incidence of 1%
or greater and more frequently than in placebo-treated
patients.
DISCUSSION
Crow’s Feet Lines Dose and Injection
Patterns: Tailoring Treatment
The approval of onabotulinumtoxinA at the 24U dose
based on the phase 3 clinical trials provides a well-founded
framework for clinical use. The presence of different CFL
patterns suggests that it may be possible to customize treat-
ment administration with the 24U dose based on the pa-
tient’s CFL pattern. In the pivotal phase 3 trials, 2 injection
patterns were offered as options to the treating physician.
Patients received injections into 3 sites per side (total of 6
injections) in the lateral orbicularis oculi muscle.8,9 The in-
jections were made with the needle bevel tip pointed up
and oriented away from the eye. Each injection was 0.1 mL
in volume and contained 4U onabotulinumtoxinA, for a
total dose of 24U.
The first injection was made approximately 1.5 to
2.0 cm temporal to the lateral canthus and just temporal to
Table 1. Composite Investigator and Patient Assessments of Crow’s Feet Lines at Maximum Smile Using the 4-Grade Facial Wrinkle Scale at Day 30 for
Responders Achieving at Least a 2-Grade Improvement From Baseline in the Pivotal Phase 3 Studies
Study OnabotulinumtoxinA 24U for CFL OnabotulinumtoxinA 24U for
CFL + 20U for GL
Placebo
Study 18 26.1% (58/222) − 1.3% (3/223)
Study 29 20.3% (62/306) 21.3% (65/305) 0% (0/306)
Figure 4. The percentage of patients who achieved grades of
none or mild on the investigator’s assessment of the severity of
crow’s feet lines as assessed at maximum smile using the
Facial Wrinkle Scale in study 1. P< .001 for
onabotulinumtoxinA 24U vs placebo at all time points.
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the orbital rim (Figure 3A). For patients with CFL above
and below the lateral canthus (ie, central fan and full fan),
the second injection was made 1.0 to 1.5 cm above the first
injection site and at an approximate 30° angle medially,
and the third injection was made 1.0 to 1.5 cm below
the first injection site and at an approximate 30° angle me-
dially. This injection pattern was also used for patients with
an upper-fan pattern.
For patients with CFL primarily below the lateral
canthus (ie, lower fan), an alternative injection pattern was
allowed at the discretion of the investigator (Figure 3B).
The first injection was made in the same manner as de-
scribed above, but the second and third injections were
given in a line angling from superoposterior to anteroinfe-
rior. The anteroinferior injection was made lateral to a line
drawn vertically from the lateral canthus and superior to
the maxillary prominence. The third injection point was
placed at the midpoint along a line connecting the supero-
posterior and anteroinferior injection points.
No data were collected in the pivotal phase 3 studies
regarding any relationship between CFL pattern and
onabotulinumtoxinA dosing pattern. Thus, it remains
to be determined whether the efficacy and safety of
onabotulinumtoxinA are affected by either the CFL pattern
or the injection pattern. Moreover, it is not known whether a
dosing pattern that focuses on the area above the lateral
canthus would be more appropriate for the small number of
patients with an upper-fan pattern. However, the efficacy
and safety results in the pivotal trials indicate that the 2 in-
jection patterns would be appropriate for more than 95% of
individuals with moderate or severe dynamic CFL. Based on
the authors’ combined clinical experience, the majority of
patients with CFL are treated using the conventional injec-
tion pattern described in Figure 3A. It should be noted that
the clinical trials described in this summary enrolled patients
with moderate-to-severe CFL. As with many clinical trials for
facial aesthetic treatment, most patients were white. Thus,
extrapolation of findings to individuals from other ethnic
groups should be madewith caution.
CONCLUSIONS
The recommended 24U onabotulinumtoxinA dose and 2 in-
jection patterns in the treatment of CFL were developed
using a rational scientific approach and are supported by
several large clinical trials. OnabotulinumtoxinA used as
suggested has proven to be safe and effective for treatment
of moderate or severe dynamic CFLs. Additionally, several
CFL patterns have been identified, with gender and
age-related differences in the frequency of patterns. The
customization permitted by the two injection patterns
allows physicians to tailor treatment of CFL based on clini-
cal presentation, their clinical expertise, and the patients’
preferences.
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